血必净注射液治疗重症肺炎的临床疗效观察

Clinical Effect of Xuebijing Injection on Severe Pneumonia

目的观察血必净注射液治疗重症肺炎患者的临床疗效。方法选取2014年8月—2015年10月解放军第474医院收治的重症肺炎患者97例,根据治疗方式不同分为常规治疗组45例和联合治疗组52例。常规治疗组患者采用常规治疗方案以及对症治疗,联合治疗组患者常规治疗组基础上给予血必净注射液;两组患者均连续治疗2周。比较两组患者临床疗效、治疗前后肺功能指标及血清炎性因子水平、不良反应发生情况。结果联合治疗组患者临床疗效优于常规治疗组(P<0.05)。治疗前,两组患者6分钟步行距离(6MWD)、用力肺活量(FVC)、第1秒用力呼气容积(FEV_1)、FEV_1/FVC、最大呼气中期流速(MMEF)及最高呼气流速(PEF)比较,差异无统计学意义(P>0.05);治疗后联合治疗组患者6MWD长于常规治疗组,FVC、FEV_1、FEV_1/FVC、MMEF及PEF均高于常规治疗组(P<0.05)。治疗前两组患者血清白介素6(IL-6)、超敏C反应蛋白(hs-CRP)和肿瘤坏死因子α(TNF-α)水平比较,差异无统计学意义(P>0.05);治疗后,联合治疗组患者血清IL-6、hs-CRP和TNF-α水平低于常规治疗组(P<0.05)。两组患者治疗期间均未发生明显肝肾功能损伤,联合治疗组仅有1例患者出现胃肠道反应。结论血必净注射液治疗重症肺炎的临床疗效确切,可有效改善患者肺功能,降低血清炎性因子水平,且安全性较高。

Objective To observe the clinical effect of xuebijing injection on severe pneumonia. Methods A total of97 patients with severe pneumonia were selected in the 474th Hospital of Chinese Peopled Liberation Army from August 2014 toOctober 2015, and they were divided into A group （ n = 45） and B group （n = 52） according to therapeutic methods. Patientsof A group received conventional treatment and symptomatic treatment, while patients of B group received extra xuebijing injectionbased on that of A group; both groups continuously treated for 2 weeks. Clinical effect, index of pulmonary function and seruminflammatory cytokines levels before and after treatment, and incidence of adverse reactions were compared between the twogroups. Results The clinical effect of B group was statistically significantly better than that of A group （ P 〈 0. 05 ）. Nostatistically significant differences of 6 - minute walk distance, FVC, FEVj , FEV j/FV C , MMEF or PEF was found between thetwo groups before treatment （ P 〉 0. 05 ） ; after treatment, 6 - minute walk distance of B group was statistically significantlylonger than that of A group, while FVC, FEVj , FEV j/FV C , MMEF and PEF of B group were statistically significantly higherthan those of A group （尸 〈0. 0 5 ）. No statistically significant differences of serum level of IL-6, hs-CRP or TNF-a was foundbetween the two groups before treatment （ P 〉 0. 05 ） , while serum levels of IL-6, hs-CRP and TNF-a of B group werestatistically significantly lower than those of A group after treatment （ P 〈 0. 05 ）. No one of the two groups occurred any obviousliver or kidney function damage during the treatment, but one of B group occurred gastrointestinal reaction. ConclusionXuebijing injection has certain clinical effect in treating severe pneumonia, can effectively improve the pulmonary function and reduce the serum inflammatory cytokines levels, and is relatively safe.